Analyst
William Blair
Equibles does not estimate personal net worth.
Miles Minter is recorded as Analyst at William Blair. Miles Minter has spoken on 4 earnings calls and 2 other investor events across 5 companies, most recently for Intellia Therapeutics, Inc. on August 6, 2026. Those appearances were for Neurocrine Biosciences Inc (NBIX), Intellia Therapeutics, Inc. (NTLA), Moderna, Inc. (MRNA), Entrada Therapeutics, Inc. (TRDA) and Axsome Therapeutics, Inc. (AXSM). The companies whose calls Miles Minter spoke on are classified in the Healthcare sector.
“I've been getting a few inbound since you published in the New England Journal on LONVOSI in HAE in the supplement. You show the ALT, ASTs over time.”
“Oh hey thanks everyone congrats on the quarter. My question is just one on clarification. I think Dr. Colino at ASCO mentioned in Interpath 001 that approximately two-thirds of patients would have micrometastatic disease.”
“I just wanted to hear your thoughts on the chronicity sort of peak opportunity here. Are you still describing that drug as a blockbuster opportunity? I only ask because recent acquisition seems to put your competitors saying that that might be a $3 billion market or greater.”
“There is high risk, but there is great reward on the other end and glad I could present Nurkren to you guys today Matt requested a standing ovation so he got one person we've got four minutes for a beauty Q&A before a breakout we'll definitely take a question from the audience kick us off please so the question has to…”
“I was just wondering whether you could comment on the actual tissue concentration of the 44 skipper that you're treating with here. You know, we did have some questions going into the data whether you were going to achieve adequate amounts here with this dose.”
William Blair
Analyst
Transcript header (unverified)
Drug Manufacturers - Specialty & Generic · Healthcare
MRNA
Biotechnology · Healthcare
